Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
112.6 DKK | -1.01% | +2.32% | +6.99% |
12/04 | Nordic Stocks Rose Friday; BioArctic Series B Climbed Highest | DJ |
11/04 | U.S. Futures Down, European Stocks Mixed | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 75.59 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.99% | 4.35B | B | ||
-3.72% | 186B | C+ | ||
-2.60% | 107B | C | ||
-3.79% | 67.44B | A | ||
+2.66% | 50.03B | B- | ||
+16.39% | 47.81B | B- | ||
+4.79% | 41.03B | B+ | ||
+1.38% | 26.85B | B | ||
+1.52% | 25.82B | A- | ||
-1.17% | 25.01B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AMBU B Stock
- Ratings Ambu A/S